Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a ...

Dubbed 'invisible' because of how it impacts people, millions suffer from Crohn's and Colitis around the world.

Charlie was given fillers in his face at 16 and has a rash across his face and body that he hasn't been able to get rid of ...

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

Chief Financial Officer Joe Wolk added that its $13.1 billion deal to acquire heart health group Shockwave Medical (NASDAQ: SWAV) also bolstered its top-line returns during the quarter, Reuters ...

Johnson & Johnson (NYSE: JNJ) stock fell 1.5%, weighed by a hefty dip in sales of its blockbuster psoriasis treatment Stelara ...

NanoDefense Pro is a topical skincare formula that supports healthy nails and skin. It is made with all-natural ingredients.

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...

SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment o ...